Omid Salahi Ardekani

Dr. Omid Salahi Ardekani

Department of Virology, Tehran University of Medical Sciences, Tehran, Tehrān, Iran
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2023 in Microbial Pathogenesis
Verified
Journal Article
Closed access
ALArash Letafati
Arash Letafati
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
HKHassan Karami
Hassan Karami
MSMina Soleimani
Mina Soleimani

12 January 2024 in Virology Journal
Verified
Journal Article
Open access
PDF file
ALArash Letafati
Arash Letafati
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
MNMina Naderisemiromi
Mina Naderisemiromi
MNMehdi Norouzi
Mehdi Norouzi
MSMohammadreza Shafiei
Mohammadreza Shafiei
SMSayed-Hamidreza Mozhgani
Sayed-Hamidreza Mozhgani
Viruses pose a constant threat to human well-being, necessitating the immune system to develop robust defenses. Natural killer (NK) cells, which play a crucial role in the immune system, have become recognized as vital participants in protecting the body against viral infections. These remarkable innate immune cells possess the unique ability to directly recognize and eliminate infected cells, thereby contributing to the early control and containment of viral pathogens. However, recent research has uncovered an intriguing phenomenon: the alteration of NK cells during viral infections. In addition to their well-established role in antiviral defense, NK cells undergo dynamic changes in their phenotype, function, and regulatory mechanisms upon encountering viral pathogens. These alterations can significantly impact the effectiveness of NK cell responses during viral infections. This review explores the multifaceted role of NK cells in antiviral immunity, highlighting their conventional effector functions as well as the emerging concept of NK cell alteration in the context of viral infections. Understanding the intricate interplay between NK cells and viral infections is crucial for advancing our knowledge of antiviral immune responses and could offer valuable information for the creation of innovative therapeutic approaches to combat viral diseases.

29 October 2024 in Virology Journal
Verified
Journal Article
Open access
PDF file
STSaeed Tajik
Saeed Tajik
AFAli Vasheghani Farahani
Ali Vasheghani Farahani
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
SSSaba Seyedi
Saba Seyedi
ZTZahra Tayebi
Zahra Tayebi
ALArash Letafati
Arash Letafati
The Zika virus (ZIKV) is classified within the Flavivirus genus of the Flaviviridae family and is categorized as an arbovirus. The virus was initially identified in a rhesus monkey in Uganda in 1947 and later in a human in Nigeria in 1952. Since 2007, the prevalence of the virus has been on the rise, culminating in a major outbreak in the United States (US) in 2015. During this outbreak, the adult population was severely impacted, experiencing a range of symptoms, including organ failure, microcephaly, fetal death, and Guillain-Barré syndrome (GBS). Additionally, skin rash, limb swelling, fever, headache, and heightened sensitivity are found in most adults with Zika syndrome. Although the virus can be transmitted through blood, vertical transmission from mother to child, and sexual contact, the primary way of transmission of the virus is through the Aedes mosquito. Cells such as neurons, macrophages, peripheral dendritic cells, and placental cells are among the target cells that the virus can infect. The TAM AXL receptor plays a crucial role in infection. After the virus enters the body through the bloodstream, it spreads in the body with a latent period of 3 to 12 days. Currently, there is no specific treatment or publicly available vaccine for the ZIKV. Limited laboratory testing has been conducted, and existing drugs originally designed for other pathogens have been repurposed for treatment. Given the Aedes mosquito's role as a vector and the wide geographical impact of the virus, this study aims to comprehensively investigate Zika's pathogenesis and clinical symptoms based on existing knowledge and research. By doing so, we seek to enhance our understanding of the virus and inform future prevention and treatment strategies.

28 April 2025 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
ALArash Letafati
Arash Letafati
SDSepehr Ebrahimi Dehkordi
Sepehr Ebrahimi Dehkordi
AFAli Vasheghani Farahani
Ali Vasheghani Farahani
MBMahshid Bahari
Mahshid Bahari
Luciano SasoLuciano Saso
Luciano Saso
Infertility has emerged as a significant global health concern, affecting nearby 8–12% of couples in reproductive age worldwide. Increasing evidence suggests a potential link between human papillomavirus (HPV) and infertility in both men and women. Some research indicate that HPV can infect various components of semen, potentially affecting sperm quality by decreasing motility, viability, and increasing DNA fragmentation, all of which may contribute to male infertility. The virus can attach to the equatorial region of the sperm head, enabling infected sperm to transmit the virus to the oocyte or placenta. Consequently, HPV potentially induces apoptosis in trophoblastic cells and disrupts their adhesion to endometrial cells, which raises the risk of miscarriage. HPV may also affect ovarian reserve by causing chronic inflammation, which can impair granulosa cell function and lower serum anti-Müllerian hormone (AMH) levels. Besides, HPV-related immune responses also contribute to infertility by producing anti-sperm antibodies (ASAs), which cause sperm clumping, reduce motility through cervical mucus, activate the complement system that damages sperm in the female reproductive tract and interfere with sperm–egg interactions. Moreover, HPV infection has been linked to reduced success rates in assisted reproductive technologies (ART), potentially disrupting critical processes such as the acrosome reaction, sperm–oocyte interaction, and fusion. One potential mechanism through which HPV contributes to infertility is oxidative stress (OS). Triggered OS can negatively impact sperm quality and cause damage to the female reproductive system, ultimately contributing to infertility. Despite these associations, the precise mechanisms and the strength of the relationship remain uncertain. Thus, this review seeks to investigate the potential impact of HPV on infertility, particularly its effects on the reproductive system through OS. A clearer understanding of these processes could inform future health strategies for addressing HPV-related infertility.

14 July 2024 in Vaccine: X
Verified
Journal Article
Open access
ALArash Letafati
Arash Letafati
MBMahshid Bahari
Mahshid Bahari
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
NJNegar Nayerain Jazi
Negar Nayerain Jazi
ANAbuzar Nikzad
Abuzar Nikzad
SMSayed-Hamidreza Mozhgani
Sayed-Hamidreza Mozhgani
Human T-lymphotropic virus type 1 (HTLV-1) is a retrovirus that is distinguished for its correlation to myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T-cell leukemia/lymphoma (ATLL). As well, HTLV-1 has been documented to have links with other inflammatory diseases, such as uveitis and dermatitis. According to the World Health Organization (WHO), the global distribution of HTLV-1 infection is estimated to extend between 5 and 10 million individuals. Recent efforts in HTLV-1 vaccine development primarily involve selecting viral components, such as antigens, from structural and non-structural proteins. These components are chosen to trigger a vigorous immune response from cytotoxic T lymphocytes (CTLs), helper T lymphocytes (HTLs), and B cells. Investigation into developing a vaccine against HTLV-1 is ongoing, and current surveys have explored several approaches, including viral vector vaccines, DNA vaccines, protein and peptide vaccines, dendritic cell-based vaccines, mRNA vaccines, and other platforms. Despite these investigations have shown promising results, challenges like the necessity for long-term protective immunity, addressing viral diversity, and managing potential side effects remain. It is critical to keep track of the progress made in HTLV-1 vaccination research to comprehend the development status and its possible impacts. The evolving nature of vaccine development underscores the importance of staying informed about advancements as we strive to combat HTLV-1-associated diseases through effective vaccination strategies. In this review, our goal is to provide an overview of the current status of HTLV-1 vaccination efforts, emphasizing the progress, challenges, and potential future directions in this vital area of research.

12 August 2024 in Virology Journal
Verified
Journal Article
Open access
PDF file
ALArash Letafati
Arash Letafati
ZTZahra Taghiabadi
Zahra Taghiabadi
Omid Salahi ArdekaniOmid Salahi Ardekani
Omid Salahi Ardekani
SASimin Abbasi
Simin Abbasi
ANAli Qaraee Najafabadi
Ali Qaraee Najafabadi
Luciano SasoLuciano Saso
Luciano Saso
The influenza virus (IFV) imposes a considerable health and economic burden globally, requiring a comprehensive understanding of its pathogenic mechanisms. Ferroptosis, an iron-dependent lipid peroxidation cell death pathway, holds unique implications for the antioxidant defense system, with possible contributions to inflammation. This exploration focuses on the dynamic interplay between ferroptosis and the host defense against viruses, emphasizing the influence of IFV infections on the activation of the ferroptosis pathway. IFV causes different types of cell death, including apoptosis, necrosis, and ferroptosis. IFV-induced ferroptotic cell death is mediated by alterations in iron homeostasis, intensifying the accumulation of reactive oxygen species and promoting lipid peroxidation. A comprehensive investigation into the mechanism of ferroptosis in viral infections, specifically IFV, has great potential to identify therapeutic strategies. This understanding may pave the way for the development of drugs using ferroptosis inhibitors, presenting an effective approach to suppress viral infections.